Krystal Biotech (KRYS) Total Current Liabilities (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Total Current Liabilities data on file, last reported at $107.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 35.62% year-over-year to $107.8 million; the trailing twelve-month figure through Mar 2026 stood at $107.8 million (up 35.62% YoY), and the FY2025 full-year result was $102.9 million, up 0.93% from the prior year.
• Total Current Liabilities climbed to $107.8 million in Q1 2026, from $102.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $107.8 million in Q1 2026 to a low of $23.9 million in Q2 2023.
• A 5-year average of $61.8 million and a median of $60.4 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 560.95% in 2022 and sank 41.96% in 2023, its largest moves.
• Tracing KRYS's Total Current Liabilities over 5 years: stood at $28.8 million in 2022, then gained by 14.72% to $33.1 million in 2023, then jumped by 208.2% to $102.0 million in 2024, then advanced by 0.93% to $102.9 million in 2025, then climbed by 4.72% to $107.8 million in 2026.
• Business Quant data shows KRYS's Total Current Liabilities at $107.8 million in Q1 2026, $102.9 million in Q4 2025, and $91.3 million in Q3 2025.